Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Today the GridTalk project launches its 8th GridBriefing at the Enabling Grids for E-sciencE (EGEE) conference in Barcelona. The report covers how information and communication technologies (ICTs), particularly computing grids, are used in the health and biomedical sectors of European research. EGEE has supported this research community since the project's birth and it is the second largest user group after physics research.
During a news conference Thursday, U.N. Secretary-General Ban Ki-moon highlighted the need to focus on the poorest people in the world even as "economists in developed nations are cautiously pointing to the first signs of renewed economic growth," the New York Times reports (MacFarquhar, 9/17).
ABC News and other outlets are reporting that two studies released on Tuesday suggest that people infected with the H1N1 virus continue to shed virus after the point where current recommendations say they can resume their normal activities.
Quidel Corporation, a global leader in point-of-care (POC) rapid diagnostic tests, issues clarification regarding the Special 510(k) clearance for an update to the Company's QuickVue Influenza A+B test package insert.
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.
As students head back to school, the CDC is reporting increasing influenza activity across the U.S. (http://www.cdc.gov/flu/weekly/). With the H1N1 vaccine not yet available, what can schools do to ease parent's minds? Communicate.
Inflation rates for healthcare supplies are projected to remain unchanged through 2010, according to an analysis released by the Premier healthcare alliance.
Nano Mask, Inc. (PINKSHEETS: NANM) today issued the following corporate update:
EdOptions (www.edoptions.com), an award-winning educational technology company, announced today that it will offer schools a built-in disaster recovery plan to provide an affordable, accessible strategy for educators to help ensure the continuity of learning.
LYSOL((R)), the number one pediatrician recommended brand, announced today the launch of the Healthier Habits Rewards Program, an initiative to educate families on healthy hygiene routines. Through the Healthier Habits Rewards program, parents can learn valuable tips to help protect themselves and their children from potential illness-causing germs at home or at school.
Meridian Bioscience, Inc., Cincinnati, Ohio today announced that the company has been granted a Special 510(k) clearance to update the TRU FLU package insert to include analytical sensitivity claims with two strains of 2009 H1N1 virus cultured from positive respiratory specimens. TRU FLU is a rapid test which identifies influenza A and B in human specimens.
The recent news that a single dose of H1N1 (swine flu) vaccine can protect adults against the virus has sparked conversations between the WHO and developed countries about sharing their vaccine stockpiles with developing countries, Bloomberg reports.
HTDS- The Company is pleased to provide the following update to its shareholders and followers on the (H1N1) Vaccine for Mellow Hope Inc, its China based subsidiary; and other general business matters.
Members of a group of Quebec researchers will be presenting the preliminary results of their work on Influenza A (H1N1) tomorrow at the Interscience Conference on Antimicrobial Agents and Chemotherapy, a prestigious international conference that the American Microbiology Association is currently presenting in San Francisco.
Quidel Corporation (NASDAQ: QDEL), a global leader in point-of-care (POC) rapid diagnostic tests, received Special 510(k) clearance for an update to the Company's QuickVue® Influenza A+B test package insert to include reactivity with culture isolates of the 2009 H1N1 Influenza A virus.
As the world braces for the coming winter flu season, health officials in Mexico expect to battle an anticipated rise in H1N1 flu cases with interactive visual communication systems from Polycom, the global leader in telepresence, video and voice communication solutions.
"Hand Washing, Not Hand-Wringing: Preparing for H1N1" is the subject of a panel discussion hosted by TOWN HALL Los Angeles on Wednesday, September 23, 2009 at the National Center for the Preservation of Democracy in downtown Los Angeles.
BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special news report on key developments at CEL-SCI Corporation.
VeriChip Corporation (“VeriChip”) and its development partner RECEPTORS LLC, a technology company whose AFFINITY by DESIGN™ chemistry platform can be applied to the development of selective binding products, announced today that VeriChip plans to fund its existing partnership with RECEPTORS to continue the development of a triage detection system for detection of the H1N1 virus.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.